Isomorphic Labs Raises $5B Series C to Advance AI Drug Design

Isomorphic Labs announced on November 17, 2026 that it had raised $5 billion in Series C funding co-led by Greenoaks and Sequoia Capital, giving the AI drug-discovery company new capital to expand its design engine and move therapeutic candidates toward clinical trials. The oversubscribed round includes Andreessen Horowitz and several other new investors, alongside another significant investment from Alphabet. Every existing investor returned: Thrive Capital, MGX, GV, CapitalG, Temasek and the…

This article has been indexed from Unite.AI